CAMBRIDGE, Mass.--(BUSINESS WIRE)--Navitor Pharmaceuticals, Inc., a biopharmaceutical company developing novel medicines that target the cellular nutrient signaling proteins regulating mTORC1 activation to treat serious diseases including neurological and fibrotic disorders, immunometabolism and certain rare diseases, today announced that George P. Vlasuk, PhD, President and Chief Executive Officer, will present a corporate overview at the Cowen and Company 38th Annual Health Care Conference in Boston on Wednesday, March 14, 2018 at 8:30 a.m. Eastern time.
About Navitor
Navitor Pharmaceuticals, Inc., is a
biopharmaceutical company discovering and developing novel medicines
that target the nutrient sensing pathways that regulate mTORC1, a master
regulator of cellular growth and metabolism. The company’s proprietary
drug discovery platform unlocks the therapeutic potential of mTOR by
bringing together deep knowledge into nutrient sensors, proprietary
biological tools and expertise regarding the correlation of mTORC1
activity in disease. Navitor’s small molecule therapeutics are designed
to selectively modulate the cellular signals that are aberrant in
disease processes caused by the dysregulation of mTORC1 activation to
address a wide range of diseases, including neurological and fibrotic
disorders, immunometabolism and certain rare diseases. Navitor’s lead
program, NV-5138 is an oral, small molecule mTORC1 activator advancing
into clinical studies for Treatment-Resistant Depression in the first
half of 2018. The company’s founding intellectual property is based on
groundbreaking discoveries related to the mTORC1 pathway and nutrient
signaling mechanisms by Dr. David Sabatini at The Whitehead Institute
for Biomedical Research and HHMI. The company is backed by leading
financial and corporate investors, including Polaris Partners, Atlas
Venture, Johnson & Johnson Innovation – JJDC, Inc., SR One, Ltd., Brace
Pharma Capital, Remeditex Ventures, Sanofi Ventures and Nan Fung
Capital. For more information, please visit www.navitorpharma.com.
